Jungsil Ro

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology · 2016 · 1.8K citations

Medicine, Oncology, Pharmacology +17

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Jungsil Ro, Fabrice André et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +10

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Giuseppe Curigliano, Harold J. Burstein, Eric P. Winer et al. · Annals of Oncology · 2017 · 1.3K citations · Full text

Medicine, Oncology, Breast Oncology +12